- Biomerica (BMRA, Financial) submits an application for a PLA code to the AMA for its inFoods® IBS test, aiming for insurance reimbursement.
- Clinical trial results published in Gastroenterology indicate significant symptom relief for IBS patients using the test.
- IBS impacts 10-15% of U.S. adults, reflecting a substantial market potential and healthcare cost challenge.
Biomerica, Inc. (BMRA), a prominent biomedical technology company, has announced a critical development in its strategy to broaden access to its inFoods® IBS diagnostic test. The company and its CLIA laboratory partner have submitted an application to the American Medical Association for a Proprietary Laboratory Analysis (PLA) code. This step is pivotal as it is expected to facilitate insurance reimbursement, thereby enhancing the test's accessibility to a wider patient base.
The inFoods® IBS test stands out as a non-invasive diagnostic tool that pinpoints patient-specific foods that provoke Irritable Bowel Syndrome (IBS) symptoms such as bloating, abdominal pain, diarrhea, and constipation. This personalized approach allows healthcare providers to recommend targeted dietary modifications, potentially alleviating symptoms and improving patients' quality of life. A clinical study published in the esteemed journal Gastroenterology demonstrated that patients adhering to diets informed by inFoods test results experienced significantly greater symptom relief compared to a placebo group.
IBS affects an estimated 10% to 15% of adults in the United States, contributing to billions in annual healthcare costs. This positions Biomerica's inFoods® platform as a promising solution in a largely underserved market, addressing a substantial unmet need for effective, personalized IBS management strategies. The product is already accessible to consumers directly at www.inFoodsIBS.com, and the company is actively engaging with gastroenterology groups and healthcare systems to encourage broader adoption.
Biomerica is optimistic that the PLA code application will pave the way for insurance reimbursement, further establishing inFoods® IBS as a groundbreaking tool in the diagnostics industry. By offering a personalized, non-pharmaceutical approach to managing IBS, Biomerica aims to create significant value not just for patients, but also for healthcare providers and shareholders alike.
